These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31749812)

  • 21. Regulation of Monocyte-Macrophage Responses in Cirrhosis-Role of Innate Immune Programming and Checkpoint Receptors.
    Riva A; Mehta G
    Front Immunol; 2019; 10():167. PubMed ID: 30804947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNASET2 as a tumor antagonizing gene in a melanoma cancer model.
    Monti L; Rodolfo M; Lo Russo G; Noonan D; Acquati F; Taramelli R
    Oncol Res; 2008; 17(2):69-74. PubMed ID: 18543608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocyte-Macrophages and T Cells in Atherosclerosis.
    Tabas I; Lichtman AH
    Immunity; 2017 Oct; 47(4):621-634. PubMed ID: 29045897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophages as a Potential Immunotherapeutic Target in Solid Cancers.
    Mishra AK; Banday S; Bharadwaj R; Ali A; Rashid R; Kulshreshtha A; Malonia SK
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor suppressor ARF regulates tissue microenvironment and tumor growth through modulation of macrophage polarization.
    Jiménez-García L; Herranz S; Higueras MA; Luque A; Hortelano S
    Oncotarget; 2016 Oct; 7(41):66835-66850. PubMed ID: 27572316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy.
    Moyes KW; Lieberman NA; Kreuser SA; Chinn H; Winter C; Deutsch G; Hoglund V; Watson R; Crane CA
    Hum Gene Ther; 2017 Feb; 28(2):200-215. PubMed ID: 27758144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-associated macrophages: a short compendium.
    Prenen H; Mazzone M
    Cell Mol Life Sci; 2019 Apr; 76(8):1447-1458. PubMed ID: 30747250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling.
    Roggiani F; Riva C; Raspagliesi F; Porta G; Valli R; Taramelli R; Acquati F; Mezzanzanica D; Tomassetti A
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30813308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
    Anfray C; Ummarino A; Andón FT; Allavena P
    Cells; 2019 Dec; 9(1):. PubMed ID: 31878087
    [No Abstract]   [Full Text] [Related]  

  • 31. The cells that mediate innate immune memory and their functional significance in inflammatory and infectious diseases.
    Gardiner CM; Mills KH
    Semin Immunol; 2016 Aug; 28(4):343-50. PubMed ID: 26979658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization.
    Smirnoff P; Roiz L; Angelkovitch B; Schwartz B; Shoseyov O
    Cancer; 2006 Dec; 107(12):2760-9. PubMed ID: 17109444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development.
    Zhou L; Tian Y; Guo F; Yu B; Li J; Xu H; Su Z
    Cancer Immunol Immunother; 2020 May; 69(5):835-846. PubMed ID: 32062693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells.
    Acquati F; Monti L; Lualdi M; Fabbri M; Sacco MG; Gribaldo L; Taramelli R
    Oncotarget; 2011 Jun; 2(6):477-84. PubMed ID: 21646684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects.
    Jia XH; Feng GW; Wang ZL; Du Y; Shen C; Hui H; Peng D; Li ZJ; Kong DL; Tian J
    Oncotarget; 2016 Apr; 7(15):20934-44. PubMed ID: 26988913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant HvRNASET2 protein induces marked connective tissue remodelling in the invertebrate model Hirudo verbana.
    Baranzini N; Weiss-Gayet M; Chazaud B; Monti L; de Eguileor M; Tettamanti G; Acquati F; Grimaldi A
    Cell Tissue Res; 2020 Jun; 380(3):565-579. PubMed ID: 32043208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.
    Yin F; Liu L; Liu X; Li G; Zheng L; Li D; Wang Q; Zhang W; Li L
    Oncol Rep; 2014 Jul; 32(1):362-72. PubMed ID: 24842157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diverse macrophages polarization in tumor microenvironment.
    Rhee I
    Arch Pharm Res; 2016 Nov; 39(11):1588-1596. PubMed ID: 27562774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer.
    Imam S; Dar P; Paparodis R; Almotah K; Al-Khudhair A; Hasan SA; Salim N; Jaume JC
    J Immunother Cancer; 2019 Jan; 7(1):3. PubMed ID: 30616690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins.
    Campomenosi P; Salis S; Lindqvist C; Mariani D; Nordström T; Acquati F; Taramelli R
    Arch Biochem Biophys; 2006 May; 449(1-2):17-26. PubMed ID: 16620762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.